Release and clinical significance of soluble CD83 in chronic lymphocytic leukemia

Abstract Soluble CD83 (sCD83), a potent immunosuppressive agent, circulates at elevated levels in some chronic lymphocytic leukemia (CLL) patients. We report that CLL patients with elevated plasma sCD83 levels had significantly shorter ( P = 0.038) treatment free survival. Culture of CLL cells with solid phase CD83 mAb + IL-4 significantly increases sCD83 release (23–117-fold, P = 0.013) and ligation of normal donor PBMC with solid phase CD83 mAb alone induces similar significant increases in sCD83 release ( P = 0.003). RT-PCR analysis detected the presence of a transcript for sCD83 in 2/3 CLL samples. These results suggest sCD83 release may play a regulatory role in CLL progression.